Skip 
Navigation Link

1215 South Walnut Ave.
Demopolis, AL 36732 map map 

Access to Care: 800.239.2901

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Decline in Antibiotic Use in Livestock Isn't Enough, Critics SayWoman's Selfie of Skin Cancer Went Viral, Sparked AwarenessCan Video Games Hone ER Docs' Skills?Higher Booze Taxes Might Pay Off for Public HealthAre Emergency Medical Workers Ready for a Nuclear Attack?Pediatric Oncologists Willing to Consider Medical MarijuanaHow to Perk Up the Holidays for Hospital PatientsWhat to Do If Someone's Bleeding BadlyAre Good Kidneys Going to Waste?U.S. Gun Sales Rose After Sandy Hook Massacre: StudyCreating Your Family Health TreeLocal Smoke-Free Laws Tied to Fewer Lung Cancer CasesYour Doc Is Away? Substitute Doctors a Safe Option, Study FindsChecking Prices for Medical Procedures Online? Good LuckPatients More Prone to Complain About Younger DoctorsPatients Often Uncomfortable With Overlapping SurgeriesClinician Denial of Patient Requests Impacts SatisfactionPatients React Poorly When Docs Say 'No'Memo to Doctors: Spit Out the Bad NewsDoubts Raised About Use of Products Containing OxybenzoneReport: Industry Hid Decades-Old Study Showing Sugar's Unhealthy EffectsMany Health Care Providers Work While SickMore Patients Are Having a Say in Their Medical CareFDA Seeks to Speed Development of 'Regenerated' Organs for Medical UseHealth Care Experts in Favor of Patient Contribution to NotesMillions Could Miss Out on a Potential Alzheimer's BreakthroughU.S. May Still Benefit From Climate AccordHealth Tip: Spread Awareness of the Opioid EpidemicKnowing Too Much About Your Genes Might Be RiskyHealth Tip: Participating in a Clinical TrialMusic, Video Help Sixth-Graders Master Hands-Only CPRIncreases in U.S. Health Spending Tied to Health Service PriceHealth Tip: Prevent Germs at the Doctor's OfficeInfo Via Social Media Apps May Increase Vaccine AcceptanceIt's 'Buyer Beware' When Purchasing Medical Pot Extract OnlineGetting Self-Driving Cars on the Road Soon Might Save LivesHealth Tip: Defining Health LiteracyDoctor Burnout: A Big Health Threat in U.S.About Half of Americans Get Health Care in ERPricing Interventions Increase Sales, Intake of Healthy FoodsHealth Tip: Get to Know Your PharmacistRobots May Be Cleaning Your Hospital Room SoonCMS Launches Initiative to Examine Impact of RegulationsPatients Prefer Face-to-Face Communication, No ComputerDrop Off Your Unused Meds Saturday on 'Take Back Day'Concerns Surround Use of Direct-to-Consumer Genetic TestingMost Patients Satisfied With Relationship With PhysicianModule Developed to Improve Adult Vaccination RatesA Drug Company's Gift Might Change How Your Doctor PrescribesAlmost 4 in 10 Tanning Salons Flout State Laws
Questions and AnswersVideosLinksBook Reviews
Related Topics

Health Insurance
Healthcare

Nearly a Third of Drugs Hit by Safety Issues After FDA Approval

HealthDay News
by -- Robert Preidt
Updated: May 10th 2017

new article illustration

WEDNESDAY, May 10, 2017 (HealthDay News) -- Safety problems emerge with nearly one in three prescription drugs after they've been approved by the U.S. Food and Drug Administration, a new study reveals.

Researchers examined data on drugs approved by the FDA between 2001 and 2010, with follow-up through 2017. The investigators found that 32 percent of the drugs had safety issues after approval.

"That is very rarely a drug withdrawal, but more commonly a black-box warning or drug safety communication issued by the FDA to let physicians and patients know that new safety information has been determined," said study leader Dr. Joseph Ross. He is an associate professor of medicine and public health at Yale University.

Of 222 drugs approved by the agency during the study period, three were withdrawn, 61 received boxed warnings and 59 prompted safety communications, the findings showed.

Drugs most likely to have post-approval safety concerns included biologics, psychiatric drugs and medicines approved through the FDA's accelerated approval process.

The report is timely because the FDA is under pressure to accelerate drug approvals, the study authors noted.

"It shows that there is the potential for compromising patient safety when drug evaluation is persistently sped up," Ross said in a university news release.

At the very least, the study should inform the ongoing debate about pre-market drug evaluation, the researchers suggested.

To assess experimental drugs for safety and effectiveness, the FDA relies on pre-market drug testing and clinical trials. Most of the trials involve fewer than 1,000 patients studied over a period of six months or less. This makes it hard to detect safety issues that might surface once more patients use the drug over a longer time period, the researchers explained.

According to study author Dr. Nicholas Downing, from the department of medicine at Brigham and Women's Hospital, in Boston, "The fact that so many new safety risks are being identified after FDA approval indicates that the FDA is taking its responsibility of ensuring the safety of new drugs throughout their lifetime seriously."

However, "these safety risks emerge, on average, four years after approval. This means that many patients are exposed to these medications before the risks become clear," Downing added in a hospital news release.

Some of those risks included serious skin reactions, liver damage, cancer and even death, the Associated Press reported.

The findings were published May 9 in the Journal of the American Medical Association.

More information

There's more about adverse drug reactions from the American Academy of Family Physicians.